Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
225.93-4.54 (-1.97%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close230.47
Bid218.00 x 100
Ask227.70 x 100
Day's Range225.89 - 232.19
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap89.46B
P/E Ratio (ttm)21.51
Avg Vol (3m)3,305,578
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • CNBC12 hours ago

    Why Jim Cramer says the hottest theme on Wall Street is your selfie stick

    Jim Cramer says the pressure for people to always look their best is driving one of the best themes on Wall Street.

  • Reuters15 hours ago

    TIMEWARNER-M&A/AT&T-LOANS-Market welcomes AT&T's $40 bln Time Warner loan

    AT&T Inc's plan to buy Time Warner Inc for $85.4 billion in the biggest global acquisition of the year will bring the second-largest U.S. bridge loan financing ever to a market hungry for mergers and acquisitions loans. The new $40 billion bridge loan backing the deal is being welcomed by bankers after a deep slump in investment-grade M&A lending in the first nine months of the year, bankers said. The loan will be lucrative for banks, led by Bank of America Merrill Lynch (BAML) and JP Morgan (JPM), that are arranging the jumbo bridge loan.

  • Barrons.com17 hours ago

    Valeant Pharmaceuticals: Stay Far Away, JPMorgan Says

    In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.